Russia plans to bring eight radiopharmaceuticals to market by 2030
In short
Russia plans to put eight radiopharmaceuticals on the domestic market by 2030, Sergei Mitin, a deputy department director at the Ministry of Industry and Trade, said at the “Bioprom” forum in Gelendzhik, according to Kommersant and TASS. Mitin said the drug “Lutetsia-177”, intended for neuroendocrine tumours, is expected to reach the market by the end of 2026 and is currently in pharmaceutical expertise. Both “Lutetsia-177” and the radionuclide cancer therapy “Radium chloride” (223 Ra) are made by Ural-based OOO “Prostor Pharma” at a UrFU site in Yekaterinburg, Kommersant reported.
Read the full story 1 min read
Russia plans to bring eight radiopharmaceuticals to the domestic market by 2030, Sergei Mitin, deputy director of a department at the Ministry of Industry and Trade, said at the “Bioprom” forum in Gelendzhik, Kommersant reported. TASS also reported the 2030 target. Kommersant did not list the eight products. [ 1 , 2 ]
Mitin said the drug “Lutetsia-177” is expected to reach the market by the end of 2026. It is currently at the stage of pharmaceutical expertise and is planned to be used for treating neuroendocrine tumours, according to Kommersant. [ 2 ]
Mitin recalled that “Radium chloride” (223 Ra), a drug for radionuclide cancer therapy, entered the domestic market for the first time last year. Kommersant reported that both “Lutetsia-177” and “Radium chloride” are products of the Ural company OOO “Prostor Pharma”, which makes them at a UrFU site in Yekaterinburg. The outlet also cited the “Pravo na zdorovye” project as saying that a phase I–II clinical trial of another “Prostor Pharma” drug, “BetaPRO” (lutetium zadavotid guraxetan), for metastatic castration-resistant prostate cancer, was registered on September 30. [ 2 ]
Bringing a radiopharmaceutical to market requires a pharmacopoeial monograph, manufacturing and quality-control standards and a defined minimum volume of research for each product, Kommersant reported. Pharmaceutical expertise is therefore only one stage, and the drug must pass procedures confirming its quality and safety before practical use, the outlet said. [ 2 ]
From 2027, the Ministry of Industry and Trade proposes launching grants of up to 250 million rubles for companies that have already registered original medicines, to cover the final stage of clinical trials, according to Kommersant. The outlet noted the mechanism could support late stages of development but is designed for the period after the stated deadline for the first drug's launch. [ 2 ]
Why it matters
The plan concerns the availability of radionuclide cancer therapies on the Russian market and the domestic production of such drugs, which Kommersant ties to the Yekaterinburg-based company “Prostor Pharma”. Kommersant also reports a proposed ministry grant of up to 250 million rubles from 2027 for late-stage clinical trials, indicating state support for drugs that have already been registered. The documents give no figures on total market size or patient numbers.
Key facts
- Eight radiopharmaceuticals are planned to be brought to the Russian market before 2030, according to Sergei Mitin, deputy director of a department at the Ministry of Industry and Trade, speaking at the “Bioprom” forum in Gelendzhik. [ 1 , 2 ]
- The drug “Lutetsia-177” is expected to reach the market by the end of 2026 and is currently at the stage of pharmaceutical expertise, according to Mitin. [ 2 ]
- “Lutetsia-177” is planned to be used to treat neuroendocrine tumours. [ 2 ]
- Mitin said the radionuclide cancer therapy “Radium chloride” (223 Ra) entered the domestic market for the first time last year. [ 2 ]
- Both “Lutetsia-177” and “Radium chloride” are products of the Ural company OOO “Prostor Pharma”, which makes them at a UrFU site in Yekaterinburg, according to Kommersant. [ 2 ]
- Kommersant, citing the “Pravo na zdorovye” project, reported that a phase I–II clinical trial of another “Prostor Pharma” drug, “BetaPRO” (lutetium zadavotid guraxetan), for metastatic castration-resistant prostate cancer was registered on September 30. [ 2 ]
- From 2027 the Ministry of Industry and Trade proposes grants of up to 250 million rubles for companies that have already registered original medicines, to cover the final stage of clinical trials, Kommersant reported. [ 2 ]
Confirmed by several sources
Still unclear
- Which radiopharmaceuticals make up the eight planned for the market by 2030. Neither document lists the products; Kommersant names only “Lutetsia-177” and refers back to “Radium chloride”.
- Whether “Lutetsia-177” will reach the market by the end of 2026 as stated. Kommersant reports the drug is still in pharmaceutical expertise and that further procedures confirming quality and safety are required before practical use; the outcome of those steps is not reported.
- Whether the proposed 2027 grant mechanism of up to 250 million rubles has been adopted. Kommersant describes it as a Minpromtorg proposal, not a decision.
- What TASS reported beyond its headline on the plan. Only the outlet's headline was available, with no article text or summary detail.